Titre : The Changing HCV Landscape: Pangenotypic Regimens
link : The Changing HCV Landscape: Pangenotypic Regimens
The Changing HCV Landscape: Pangenotypic Regimens
Review Articles
MAY 18, 2017
MAY 18, 2017
The Changing HCV Landscape: Update on Treatment
Toward the Future: Pangenotypic Regimens
A novel once-daily RBV-free doublet regimen of ABT-493 (a protease inhibitor) and ABT-530 (an NS5A inhibitor) was studied in an intent-to-treat population of treatment-naive and treatment-experienced patients for 8 to 12 weeks (phase 2 SURVEYOR-1 and SURVEYOR-2). Both drugs are second-generation members of their respective classes, with pangenotypic coverage and coverage of most or all known RAVs relevant to their classes. The results are summarized as follows: SVR12 by 97% to 98% with 8 weeks of treatment in GT1 and GT2 noncirrhotic patients by intention-to-treat analysis,64 96% SVR12 in GT1 patients with cirrhosis treated for 12 weeks,65 and 100% SVR4 for patients with GT4-6 without cirrhosis treated for 12 weeks.66 Additional studies in GT3 patients yielded SVR12 in 97% of noncirrhotics treated for 8 weeks,67 and 100% in cirrhotics treated for 12 weeks.68 These data from phase 2 trials reflect the potential for this regimen to be available in the future as a truly pangenotypic regimen without RBV if phase 3 trials recapitulate these results. A fixed-dose coformulated regimen consisting of SOF-VEL and GS-9857 (a second-generation NS5A inhibitor) received breakthrough therapy designation by the FDA for the treatment of chronic GT1 patients who have previously failed an NS5A-containing regimen. Lawitz et al treated 128 GT1-6 patients, mostly with GT1-3, including 48% with cirrhosis for 12 weeks with the triplet regimen.69 Nearly 80% of patients had prior DAA exposure, including 63 of 63 GT1 patients (100%), and 60% had baseline RAVs. Overall, 127 of 128 (99%) attained SVR12, with the only virologic failure in a GT3 patient. Of 35 patients with prior NS5A exposure, all had SVR12.
Thus articles The Changing HCV Landscape: Pangenotypic Regimens
that is all articles The Changing HCV Landscape: Pangenotypic Regimens This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article The Changing HCV Landscape: Pangenotypic Regimens the link address https://newsaninpiration.blogspot.com/2017/05/the-changing-hcv-landscape-pangenotypic.html
Related Posts :
Pentagon Outs American Troops In Syria Via Twitter: Syrian SITREP- Reported by Jules Levin - Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs
- Diabetes is associated with an increased risk of cancer and reduces post-cancer survival
- Premiere Stages seeking scripts for the 2019 Premiere Play Festival
- Impatient patients turn to online 'buyers club' for new drugs
0 Response to "The Changing HCV Landscape: Pangenotypic Regimens"
Post a Comment